Organization | Zyla Life Sciences

Zyla Life Sciences Report issue

For profit Phase 1 Phase 2 Phase 3

Founded: Vaerlose Denmark (1995)

Status: Acquired by Assertio (2020)

Organization Overview

First Clinical Trial

2002

NCT01356212

First Marketed Drug

1995

indomethacin (indocin)

First NDA Approval

None

Last Known Activity

2017

Timeline

NOW

Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

EGALET | Egalet Ltd | ZYLA | ZYLA LIFE SCIENCES

Active Ingredients

Marketed Drugs (6)

diclofenac (voltaren) (2013)

indomethacin (indocin) (1965)

ketorolac (acuvail) (2010)

meloxicam (mobic) (2015)

morphine (2017)

oxycodone (oxycontin) (2011)

Drugs in Phase 3 Trials (2)

ketorolac (acuvail) (11 trials)

oxycodone (oxycontin) (3 trials)

Drugs in Phase 2 Trials (2)

carvedilol (coreg) (1 trial)

morphine (2 trials)

Drugs in Phase 1 Trials (5)

acetaminophen (tylenol) (1 trial)

fluticasone (cutivate) (1 trial)

hydrocodone (hycodan) (1 trial)

lidocaine (xylocaine) (1 trial)

oxymetazoline (ocuclear) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Back Pain (Phase 3)

Essential Hypertension (Phase 2)

Hypertension (Phase 2)

Low Back Pain (Phase 3)

Migraine Disorders (Phase 2)

Pain, Postoperative (Phase 3)

Tooth, Impacted (Phase 2)

Overview

Highest Phase: Phase 3
# of Trials: 18
# of Trial APIs: 9